

Table (1): Distribution of aberrant CD markers in studied populations:

Variables	AML N=32	B-ALL N=15	T-ALL N=3
HLADR	17 (53.13%)	-	1 (33.33%)
CD19	3 (9.38%)	-	1 (33.33%)
CD13	-	3 (20.00%)	1 (33.33%)
CD33	-	2 (13.33%)	1 (33.33%)
CD14	-	1 (6.67%)	-
CD5	2 (6.25%)	-	-
CD7	9 (28.13%)	-	-
CD117	-	1 (6.67%)	-
CD3	1 (3.13%)	-	-
TdT	2 (6.25%)	-	-

Table (2): Frequency of lymphoid marker in subclass of AML patient in FAB study

FAB	T cell markers				B cell markers			
	CD5	CD2	CD3	CD7	CD19	CD20	CD22	CD10
M0	0	0	0	0	0	0	0	0
M1	0	0	0	0	0	0	0	0
M2	0	0	1	1	0	0	0	0
M3	0	0	0	2	0	0	0	0
M4- M5	2	0	0	3	3	0	0	0
M6	0	0	0	2	0	0	0	0
M7	0	0	0	1	0	0	0	0